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Abstract The dual role of ErbB2 (or HER-2) in tumor
growth and in physiological adaptive reactions of the heart
positions ErbB2 at the intersection between cancer and
chronic heart failure. Accordingly, ErbB2-targeted inhibi-
tory therapy of cancer may lead to ventricular dysfunction,
and activation of ErbB2 for heart failure therapy may
induce malignancy. The molecular processes leading to the
activation of ErbB2 in tumors and cardiac cells are, how-
ever, fundamentally different from each other. Thus, it
must be feasible to design drugs that specifically target
either physiological or malignant ErbB2 signaling, to
activate ErbB2 signaling in heart failure with no increased
risk for cancer, and to inhibit ErbB2 signaling in cancer
with no increased risk for heart failure. In this review, we
present a state-of-the-art on how ErbB2 is regulated in
physiological conditions and in tumor cells and how this
knowledge translates into smart drug design. This leads to a
new generation of drugs interfering with ErbB2 in a unique
way tailored for a specific clinical goal. These exciting
developments at the crossing between cancer and heart
failure are an elegant example of interdisciplinary collab-
orations between clinicians, physiologists, pharmacolo-
gists, and molecular biologists.
Keywords Neuregulin-1  ErbB2 signaling 
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Introduction
The ErbB2 (or HER2) receptor is overexpressed in 25 % of
breast tumors and is a major drug target in cancer therapy.
Trastuzumab (Herceptin) was the first anti-ErbB2 drug to
be approved by the FDA. Unexpectedly, patients receiving
trastuzumab were found to have a high incidence of heart
failure, especially when combined with anthracyclines.
This observation led to the discovery of the protective
ErbB/NRG-1 system in cardiovascular physiology. The
combined role of ErbB2 in malignant tumor growth, and in
compensatory processes in the heart, positions ErbB2 at the
crossing between cancer and heart failure. Hence, phar-
macological inhibition of ErbB2 to treat cancer may induce
heart failure, while systemic activation of ErbB2 to treat
heart failure may induce malignancy. ErbB2 belongs to the
family of human epidermal growth factor (EGF) receptors
consisting of EGFR (ErbB1), ErbB2, ErbB3, and ErbB4
(Fig. 1). As opposed to its family members, ErbB2 has no
known ligand, instead, it has a permanent open confirma-
tion, continuously exposing a dimerization arm for inter-
action with another ErbB family member (heterotypic
ErbB signaling). ErbB3 is a kinase-impaired receptor and
requires another dimerization partner for activation.
Despite this general theme, the principles of ErbB2
signaling in physiological conditions, including the regu-
lation of cardiac function, are fundamentally different from
those in cancer cells [10]. This suggests that it must be
feasible to specifically interfere with either physiological or
oncogenic ErbB2 signaling, to activate ErbB2 signaling in
heart failure with no increased risk for cancer on the one
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hand, and to inhibit ErbB2 signaling in cancer with no
increased risk for heart failure on the other hand. Smart
drug design developed in a stepwise fashion has now
provided at least seven different anti-ErbB2 cancer drugs,
together with a few molecules to activate physiological
ErbB2 signaling for the treatment of heart failure. Each of
these drugs interferes with ErbB2 in a unique way. In this
review, we present a comprehensive overview of these
developments at the crossing between cancer and heart
failure. We will address the biology of ErbB signaling in
cancer and cardiac cells, the regulatory aspects and clinical
benefits of NRG-1/ErbB signaling activation in heart fail-
ure, and the working mechanisms of different anti-ErbB2
drugs and their degree of cardiotoxicity.
ErbB2 signaling in the heart
Myocardial ErbB2 signaling is elementary during fetal
development, adaptation, and, perhaps, even regeneration
of the heart [9, 31, 41]. In adult life, myocardial ErbB2 is
part of an endothelium-controlled NRG-1/ErbB signaling
axis, in which NRG-1, secreted from cardiac endothelial
cells, binds to ErbB4 and/or ErbB3 in the myocardial tissue
[6, 10]. In neonatal hearts, ErbB2 and ErbB4 are highly
expressed, but they progressively decrease 1 week after
birth. ErbB3 expression is more stable, and may even be
higher throughout the postnatal development [6, 9].
Although NRG-1 signaling has generally been attributed to
signaling effects mediated by ErbB4, recent data suggest
that ErbB3 cannot be ignored [61]. As opposed to ErbB4,
however, ErbB3 cannot signal through homodimers and
always requires another ErbB dimerization partner to ini-
tiate intracellular signaling.
Following binding of ErbB4 to NRG-1, ErbB4 under-
goes a conformation switch from a closed conformation to
an open conformation, exposure of a dimerization arm in
subdomain II, formation of ErbB4/ErbB2 heterodimers,
increased ErbB4/ErbB2 tyrosine kinase activity, and trans-
phosphorylation of the ErbB cytoplasmic signaling tails
(Fig. 2a). Although ErbB2 is the preferred dimerization
partner of ligand-activated ErbB4, NRG-1 may also induce
the formation of ErbB4 homodimers (homotypic ErbB
signaling) or ErbB4/ErbB3 heterodimers, and has such
signal in an ErbB2-independent way. The relative contri-
bution between both homotypic and heterotypic signaling
by NRG-1 is unknown. It is also not known whether the
relative contribution of homo- and heterodimer signaling
and the ratio between ErbB2, ErbB3, and ErbB4 may
Fig. 1 ErbB receptors. Human
epidermal growth factor
receptors consist of EGFR
(ErbB1), ErbB2, ErbB3, and
ErbB4. ErbB receptors share
high homology in the
extracellular domain and the
kinase domain. However,
ErbB3 lacks tyrosine kinase
activity and ErbB2 has no
known ligand, instead, it has a
constitutive open conformation,
continuously exposing a
dimerization arm for interaction
with another ErbB family
member. NRG-1, secreted from
cardiac endothelial cells, can
bind to ErbB3 and ErbB4
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change in certain conditions. As further explained below,
experiments with bivalent NRG-1 have shown that homo-
typic NRG-1 signaling (through ErbB4/ErbB4 homod-
imers) may be sufficient for cardioprotection [27].
Receptor homo- or heterodimerization triggers the activa-
tion of signaling pathways, such as the phosphoinositide
3-kinase (PI3K)/Akt, Ras/Extracellular signal-regulated
kinases (ERK), and proto-oncogene tyrosine-protein kinase
(Src)/focal adhesion kinase (FAK) pathway. NRG-1/ErbB
signaling protects cardiomyocytes from apoptosis and
stimulates NO production through PI3K/Akt signaling. It
also induces cardiomyocyte growth and proliferation
through both PI3K/Akt and ERK1/2 signaling (Fig. 3a)
[47].
The NRG-1/ErbB signaling axis is activated in heart
failure, and compensates for maladaptive processes that lead
to the progression of cardiac dysfunction, at least during the
early stages of the syndrome [30, 31]. Recently, D’Uva et al.
showed that the mechanism of ErbB2-mediated cardiopro-
tection may be subdivided into regeneration by increased
cardiomyocyte dedifferentiation and proliferation (which
was ERK-dependent), and the induction of hypertrophy and
cell survival (which is both Akt- and ERK-dependent) [9].
They also showed that transient reactivation of ErbB2 sig-
naling after myocardial infarction promotes heart regenera-
tion, which after ErbB2 signaling termination, resulted into
cardiomyocyte redifferentiation and tissue replacement with
reduced scarring [9]. This study suggests that tuning ErbB
signaling in the correct way could provide an optimal route
for maximizing endogenous regeneration capacity of the
injured adult heart. Of note, Ku¨hn et al. demonstrated that
these regenerative effects of NRG-1 are more pronounced
during the neonatal period than in adulthood [44]. Interest-
ingly, another series of recent experiments indicate that,
apart from healing the heart, the activation of ErbB signaling
with systemic NRG-1 may also mitigate common co-
Fig. 2 ErbB signaling in ErbB2-overexpressing breast cancer cells
and in cardiomyocytes. a In adult cardiomyocytes, NRG-1 binding to
ErbB4 induces a switch from a closed to the open receptor
conformation, exposing a dimerization arm (domain II). Ligand-
activated ErbB4 results in the formation of either ErbB2/ErbB4
heterodimers or ErbB4/ErbB4 homodimers. This leads to the
phosphorylation of specific tyrosines in the tail region, and the
activation of downstream proteins and cardioprotective signaling
cascades. b Oncogenic signaling in breast cancer cells can be
mediated by overexpressed ErbB2. Amplified ErbB2 triggers pre-
dominantly ligand-independent oncogenic ErbB2/ErbB3 heterodi-
mers. This leads to the phosphorylation of specific tyrosines in the tail
region of the receptors, and the activation of downstream proteins and
pro-neoplastic signaling
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morbidities of heart failure, including diabetes, atheroscle-
rosis, pulmonary hypertension, and renal dysfunction
[12, 40, 56, 59]. These effects are most likely mediated by
acting on local tissue ErbB receptors in the liver, skeletal
muscle cells, kidney cells, and vascular cells [42, 56].
Accordingly, apart from its effects on the failing heart, NRG-
1 may have pleiotropic actions in several organs and
pathophysiological processes throughout the organism. If
confirmed in humans, on top of the standard therapy, NRG-1
treatment may take a particular position in the pharmaco-
logical therapy of heart failure aimed at regenerating the
injured heart and mitigating its co-morbidities. NRG-1 has
been used in many animal models of heart failure and is
currently tested in phase III clinical trial in heart failure with
a reduced left ventricular ejection fraction (Table 1-2) [41].
In these trials, NRG-1 is administrated as EGF-domain
fragment of recombinant human (rh)NRG-1b or as an Ig
domain-containing version of NRG-1b known as glial
growth factor 2 (GGF2), usually by intravenous infusions.
A concern during pharmacological ErbB signaling
activation in heart failure is, however, a potential stimu-
lation of tumor growth. As explained below, tumor growth
in ErbB2-amplified cells mainly results from the ligand-
independent formation of ErbB2/ErbB3 oncogenic com-
plexes. Therefore, at first glance, NRG-1 should not induce
oncogenic complexes, and the risk to induce malignancy
should be limited. However, NRG-1 also binds to ErbB3 on
cancer cells forcing it to the ‘‘open conformation’’ and
favoring formation of new oncogenic complexes. In this
scenario, NRG-1 may advance tumor growth and/or pro-
mote tumor resistance during treatment with anti-ErbB2
therapies. A recent study contradicts this hypothesis.
Ganapathy et al. demonstrated that rhNRG-1 administra-
tion in the first month of life, sufficient for stimulating
cardiac regeneration, did not induce unwanted extra-car-
diac neoplastic growth or the early stage neoplastic foci
within 6 months [16].
Smart drug design to activate ErbB signaling
without inducing cancer
In an attempt to design a translationally relevant ErbB
agonist for the treatment of chronic diseases, such as
heart failure, Griffith and Lee created bivalent NRG-1b
Fig. 3 Intracellular signaling cascades following the activation of
ErbB receptors in cardiomyocytes and cancer cells. a ErbB receptor
homo- or heterodimerization in cardiomyocytes triggers the activation
of Ras/ERK, PI3K/Akt and Src/FAK signaling pathways. NRG-1/
ErbB signaling in cardiomyocytes regulates structure, function,
growth, proliferation and survival [1, 39]. b Oncogenic signaling
through ErbB2 homodimers or ErbB2-ErbB3 heterodimers induces
the activation of Ras/ERK and PI3K/Akt signaling pathways. PI3K/
Akt signaling has a central oncogenic role as its robust activation
induces intense cell growth and proliferation [55]. Src proto-oncogene
tyrosine-protein kinase, FAK focal adhesion kinase, Grb2 Growth
factor receptor-bound protei-2, Sos Son of sevenless, MEK mitogen-
activated ERK kinase, ERK extracellular signal-regulated kinase,
PI3K phosphatidyl inositol-3 kinase, PIP3 phosphatidyl inositol
(4,5,6)-triphosphate, PDK1 phosphoinositide dependent protein
kinase-1, Akt protein kinase B, eNOS endothelial nitric oxide synthase
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(MM) [26, 27]. NN is a ligand for both ErbB3 and ErbB4
and drives particular homotypic interactions at the
expense of others. This alters signaling and phenotypic
outcomes compared with their native, monovalent
counterparts. In cardiac cells, NN will predominantly
promote the homotypic association of ErbB4, thereby
reducing signaling through ErbB2/ErbB4 heterodimers
(Fig. 4a). In tumor cells, NN drives a stable, homotypic
association of ErbB3, which traps ErbB3, keeping it
away from undesirable oncogenic signaling with ErbB2.
ErbB3 has a weak kinase activity, and hence, ErbB3
homodimers are incapable of activating downstream
signaling pathways (Fig. 4b). Consistently, NN induced
anti-neoplastic or cytostatic responses in cancer cells
[27]. The differences between the action of monovalent
NRG-1 and bivalent NN are summarized in Table 3.
Subsequent studies showed that NN significantly atten-
uated doxorubicin-induced cardiac dysfunction,
Table 1 Administration of rhNRG-1 in animal models of heart failure
Model Species RhNRG-1 treatment Outcome
MI [37] Rat 10 lg/kg day i.v. for 5 or 10 days,
1 week or 2 months
after LAD ligation
Improved LV structure and dysfunction
Increased angiogenesis
Improved survival
MI [2] Mouse 2.5 lg/mouse i.p. for 12 weeks,
1 week after LAD
Improved LV structure and dysfunction
Increased myocardial regeneration
MI [19] Rat 5 lg/kg h i.v. for 7 days,
8 weeks after LAD ligation
Improved LV structure and dysfunction
MI [20] Rat 10 lg/kg day i.v. for 10 days,
4 weeks after LAD ligation








MI [15] Swine 0.67 mg/kg i.v. every 2 days for
4 weeks, 1 week after MI
Improved LV dysfunction
Decreased fibrosis





Myo-carditis [37] Mouse 30 lg/kg day i.v. for 5 days Improved LV structure and dysfunction
Decreased necrosis
Improved survival
Doxo-induced CM [37] Rat 20 lg/kg.day i.v. for 5 days, 4 weeks
after first doxorubicin administration
Improved LV structure and dysfunction
Decreased necrosis
Improved survival
Doxo-induced CM [3] Mouse 0.75 mg/kg day s.c. for 3–5 days,
1 day before doxo administration




Pacing-induced CM [37] Dog 3 lg/kg day i.v. for 5 days
with continuous pacing, 3 weeks after
starting rapid pacing
Improved LV dysfunction
Pacing-induced CM [34] Rhesus monkey 3 lg/kg day i.v. for 10 days Improved LV dysfunction
Increased myosin heavy chain a
Type 1 DCM [33] Mouse 10 lg/kg i.v. every 2 days for
2 weeks, 12 weeks after STZ
injection
Improved LV structure and dysfunction
Decreased apoptosis
Decreased fibrosis
RhNRG-1 Recombinant human neuregulin-1, MIMyocardial infarction, I.v. Intravenous, LAD Left anterior descending artery, LV Left ventricle,
I.p., Intraperitonea, I/R Ischemia/Reperfusion, Doxo Doxorubicin, S.c. Subcutaneous, CM Cardiomyopathy, DCM Diabetic cardiomyopathy, STZ
Streptozotocin
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Table 2 Clinical trials with rhNRG-1 as a therapy for heart failure
Description Dosage Outcome
Phase II, randomized, double-blind,
multicenter, background-therapy-based,
placebo-controlled, parallel group study
[17]
0.3, 0.6 or 1.2 lg/kg 10
h i.v. infusion, 10 consecutive days
Improved and sustained LVEF % and
decreased LVEDV and LVESV at 30
and 90 days after treatment
Single-center, prospective, non-
randomized, open label study [25]
Initial dose of 1.2 lg/kg for 6 h
0.6, 1.2 or 2.4 lg/kg for 12 h i.v.
infusion, 10 consecutive days
Acute increase in CO
Improvement in LVEF
I.v. Intravenous, LVEF % % Left ventricle ejection fraction, LVEDV Left ventricle end-diastolic volume, LVESV Left ventricle end-systolic
volum, CO Cardiac output
Fig. 4 Effect of bivalent NRG-
1b (MM) in ErbB2-
overexpressing breast cancer
cells and cardiomyocytes. a In
cardiac cells, NN will
predominantly promote
homotypic association of
ErbB4, but signaling through
ErbB2/ErbB4 heterodimers will
be reduced. ErbB4 homotypic
signaling seems to be sufficient
for cardioprotective signaling.
b In tumor cells, MM drives a
stable, homotypic association of
ErbB3, which traps ErbB3,
keeping it away from
undesirable oncogenic signaling
with ErbB2. ErbB3 has a weak






cytostatic responses in cancer
cells
Table 3 Differences in the mechanism of monovalent NRG-1 compared with bivalent NRG-1
Drug Tumor cell Cardiomyocyte
Neuregulin-1 (NRG-1) NRG-1 stimulation may increase malignant
potential of ErbB2-expressing cancer cells by
inducing ErbB2 and ErbB3 heterotypic, pro-
neoplastic interactions
NRG-1 is cardioprotective by inducing ErbB2/
Erbb4 heterotypic and ErbB4/ErbB4
homotypic interactions
Bivalent NRG-1 (NN) NN decreases migration, inhibits proliferation
and increases apoptosis in ErbB2-expressing
cancer cells by trapping ErbB3 for homotypic,
weak/non-signaling interactions
NN is cardioprotective by inducing ErbB4
homotypic interactions
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indicating that ErbB4 homodimer signaling suffices for
cardioprotection or, alternatively, that there remains
enough ErbB2/ErbB4 signaling for a normal activity
[27].
Accordingly, given the reduced pro-neoplastic potential
of NN versus rhNRG-1, NN has translational potential for
the treatment of chronic diseases, such as heart failure, with
no increased risk to induce cancer.
ErbB2 signaling in cancer
In many different cancer cells, ErbB2 is amplified by
increased gene transcription. Tumor growth is critically
dependent on ErbB2 amplification, a process coined
oncogenic addiction of malignancy. Amplified ErbB2 can
bind to ErbB3 in an uncontrolled and at least partially
ligand-independent way, forming an oncogenic ErbB2/
ErbB3 complex (Fig. 2b) [22]. In this complex, following
phosphorylation of ErbB3 tyrosine residues by the ErbB2
kinase, ErbB3 interacts with the regulatory p85 subunit of
PI3K without requirement of any adaptor proteins [46].
This results in the robust activation of the PI3K/Akt
pathway and intense cell growth and proliferation, posi-
tioning ErbB3 as the key node in oncogenic ErbB2 sig-
naling (Fig. 3b). This scenario is identified in 20–30 % of
invasive breast carcinomas, and in significant cases of
ovarian, gastric, and bladder cancer.
ErbB2 has been the main therapeutic target within the
ErbB2/ErbB3 oncogenic unit. The goal of ErbB2-targeted
therapy is to interrupt PI3K/Akt signaling to stop cell
proliferation and induce cell apoptosis. Clinical introduc-
tion of this strategy with the humanized anti-ErbB2 anti-
body trastuzumab (Herceptin) has been successful, but
chronic treatment has been disturbed by unforeseen prob-
lems, namely, (a) the development of tumor drug resistance
and (b) the induction of cardiac dysfunction and heart
failure [23]. These drawbacks have forced the design of
newer anti-ErbB2 drugs.
A first challenge has been to intercept biological escape
routes leading to anti-ErbB2 drug resistance. Recent evi-
dence suggests that the upregulation of ErbB3 is critically
involved in the process [51]. ErbB3 mRNA transcription is
Fig. 5 Trastuzumab resistance. a Trastuzumab provides an ErbB3
escape route for the development of tumor resistance. When inhibiting
ErbB2 signaling, ErbB3 expression will be upregulated to form new
oncogenic complexes with ErbB2, especially when NRG-1 or another
ErbB3 ligand is available to open its conformation. Consistently, both
the upregulation of ErbB3 mRNA and the concentration of NRG-1 in
tumor predict trastuzumab drug resistance. b Biparatopic ErbB2
trapping blocks all ligand-dependent and ligand-independent dimers of
ErbB2. Pan-ErbB2 inhibition will stop PI3K/Akt signaling and avoid
compensatory responses that lead to drug resistance
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negatively controlled by ErbB2 signaling, explaining why
ErbB3 is upregulated during the suppression of ErbB2
signaling (Fig. 5a) [18]. Enhanced ErbB3 forms new
oncogenic complexes with residually active ErbB2, which
maintains oncogenic signaling and endorses anti-ErbB2
drug resistance [46]. This mechanism is especially intense
when autocrine or paracrine NRG-1 is available in the
tumor [45]. When NRG-1 binds to ErbB3, its conformation
switches to the open conformation as such boosting
dimerization of ErbB3 with the remaining active ErbB2.
Thus, to avoid drug resistance, it seems compulsory to
combine specific anti-ErbB2 therapy with anti-ErbB3
interventions, or to engineer bispecific anti-ErbB drugs that
inhibit both ErbB2 and ErbB3 in a combined fashion. A
recent study showed that trapping ErbB2 in a dimerization-
incompetent state will also result into obstruction of all
ligand-dependent and ligand-independent ErbB2/ErbB3
complexes (Fig. 5b). This pan-ErbB2 inhibition was shown
to disarm all compensatory mechanisms and, therefore, to
avoid the development of drug resistance [55].
A second challenge has been to avoid anti-ErbB2 car-
diotoxicity. As explained above, ErbB2 signaling is
important for cardiac physiology, especially in the condi-
tions of cardiac overload and injury. However, as opposed
to tumor cells, cardiac ErbB2 signaling is critically ligand
(NRG-1)-dependent. This suggests that, as long as inhibi-
tory anti-ErbB2 treatment does not interfere with ligand-
dependent ErbB2 signaling, its cardiac profile may be safe
[10].
Trastuzumab: The first ErbB2-targeted drug,
how does it work, where does it fail?
The clinical picture
Trastuzumab (Herceptin) is an effective anticancer treat-
ment for ErbB2-overexpressing breast cancer in the adju-
vant, neo-adjuvant, and metastatic settings. Adding the
conventional chemotherapeutics increases the overall
response to trastuzumab. In the adjuvant setting, based on
several phase III trials, treatment with trastuzumab is given
for 1 year. In the first human trials of trastuzumab, however,
an unexpected cardiac toxicity was identified: 27 % of
patients receiving trastuzumab concurrently with anthracy-
cline-containing chemotherapy developed either asymp-
tomatic cardiomyopathy or clinical heart failure compared
with 7 % of patients receiving anthracycline chemotherapy
alone [17, 49, 52]. Fortunately, in many cases, the cardiac
dysfunction was asymptomatic, and further clinical trials
indicated that in the absence of concomitant anthracycline
treatment, the incidence of cardiac dysfunction was rela-
tively low during treatment with trastuzumab, generally
transient after the completion of therapy. In addition, the
cardiac risks were outweighed overall by the potent anti-
cancer effect of trastuzumab treatment [1].
Trastuzumab is a monoclonal antibody that binds to
subdomain IV of ErbB2 (Fig. 6a). This binding disrupts
ligand-independent ErbB2/ErbB3 interactions in ErbB2-
amplified cells and subsequently impedes PI3K/Akt activ-
ity [23, 28]. However, it is yet uncertain whether this is the
only mechanism responsible for trastuzumab’s in vivo
cancer-inhibiting actions. Other proposed mechanisms
include increased endocytotic destruction of ErbB2,
reduced shedding of the extracellular domain of ErB2 and
immune activation by recruiting Fc-competent immune
effector cells, and other components of antibody-dependent
cell-mediated cytotoxicity (ADCC) [23].
Due to the monoclonal humanized nature of trastuzu-
mab, this antibody can only be studied on human cells.
This explains why it has remained long unclear whether
trastuzumab also interferes with NRG-1-dependent physi-
ological ErbB signaling in the heart. Recently, however,
using human fetal cardiomyocytes, Fedele and coworkers
showed that trastuzumab, indeed, inhibited the formation
of NRG-1-induced ErbB4/ErbB2 complexes [14]. This
observation most likely explains why trastuzumab’s car-
diac toxicity primarily occurs when it is given simultane-
ously with anthracyclins. Indeed, NRG-1/ErbB signaling in
the heart is part of a stress-activated compensatory system,
playing a modest role in physiological conditions, but
becoming indispensable in the injured heart, e.g., during
ischemia or exposure to cardiotoxic agents, such as
anthracyclins [21, 36].
Another disadvantage of trastuzumab’s working mech-
anism is that it provides an ErbB3 escape route for the
development of tumor resistance. Upon inhibition of ErbB2
signaling, ErbB3 expression is upregulated, and forms new
oncogenic complexes with ErbB2, especially when NRG-1
or another ErbB3 ligand is available to open its confor-
mation. Consistently, both the upregulation of ErbB3
mRNA and the concentration of NRG-1 in tumor predict
trastuzumab drug resistance (Fig. 5) [46].
Accordingly, trastuzumab is an effective drug to inhibit
malignant signaling in ErbB2 overexpressing tumor cells,
but it has the disadvantage of (a) interfering with NRG-1/
ErbB2 signaling in the heart, which becomes harmful
during co-treatment with antracyclines, and (b) allowing an
ErbB3-dependent escape route for drug resistance through
the upregulation of ErbB3 and formation of ligand-induced
ErbB2/ErbB3 oncogenic complexes.
How do next generation ErbB2 antagonists differ
from trastuzumab?
During the past decade, we havewitnessed the introduction of
several new drugs to target ErbB2 in cancer. These drugs
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include new monoclonal antibodies against ErbB2 (per-
tuzumab, MM-111), oral small molecules ErbB tyrosine
kinase inhibitors (lapatinib, afatinib, and neratinib), and an
antibody–drug conjugate of trastuzumab combined with a
cytotoxic agent, emtansine. Each of these molecules has a
specific mode of action at the level of the ErbB receptors,
hence influencing ligand-dependent and ligand-independent
ErbB signaling in a unique way (Fig. 6). Specific activity
profiles allow predicting their effect on tumor growth, the
potential development of drug resistance, and their interfer-
encewith physiologicalNRG-1-inducedErbB signaling in the
heart and other organs. In the next paragraphs, we have
compiled these profiles, and summarized them in Table 4.
Pertuzumab
The clinical picture
The combination of pertuzumab plus trastuzumab plus
docetaxel, as compared with placebo plus trastuzumab plus
docetaxel, when used as the first-line treatment for ErbB2-
positive metastatic breast cancer, significantly prolongs
progression-free survival. In the phase III randomized,
double-blind, multinational CLEOPATRA trial, per-
tuzumab plus trastuzumab did not increase cardiac toxic
effects [54]. Pertuzumab has not been tested in co-admin-
istration with anthracyclins.
Fig. 6 Primary actions of current ErbB2 inhibitors. a Trastuzumab is
a humanized monoclonal antibody to subdomain IV of ErBb2. This
leads to the inhibition of ligand-independent ErbB2 signaling.
b. Pertuzumab is a humanized monoclonal antibody to subdomain
II of the dimerization arm of ErbB2. Pertuzumab leads to the
inhibition of ligand-induced ErbB2 signaling. c. Lapatinib is a small
molecule tyrosine kinase inhibitor of EGFR (ErbB1) and ErbB2.
Afatinib and neratinib are two second-generation irreversible tyrosine
kinase inhibitors. Afatinib is highly selective for EGFR/ErbB1 and
ErbB2, whereas neratinib also inhibits ErbB4. Tyrosine kinase
activity is blocked independently of whether this activity is ligand-
induced or not. d Trastuzumab-emtansine is an antibody conjugate
consisting of the monoclonal antibody trastuzumab linked to cycto-
toxic agent emtansine, an antimicrotubule drug. e MM-111 is a
bispecific antibody and polypeptide fusion protein of two human scFv
antibodies linked to modified human serum albumin. MM-111 forms
a trimeric complex with ErbB2 and ErbB3, inhibiting ligand-
dependent ErbB2 and ErbB3 signaling
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Pertuzumab is a monoclonal antibody binding to sub-
domain II of ErbB2, hence, interfering specifically with
ligand-induced ErbB2 dimerization (Fig. 6b) [10]. This
working mechanism makes it a perfect drug to be com-
bined with trastuzumab, as it will complementary inhibit
the formation of ligand-induced ErbB2/ErbB3 oncogenic
complexes arising after the upregulation of ErbB3 by
trastuzumab [28]. This phenomenon most likely explains
the success of the combination of trastuzumab and per-
tuzmab in the clinic: a prolonged survival of patients with
metastatic breast cancer when pertuzumab was added to a
treatment with trastuzumab and anthracyclines [7].
In contrast to trastuzumab, pertuzumab will also inter-
fere with physiological ligand-induced ErbB2 signaling
and as such potentially abrogate the protective actions of
NRG-1 in the heart [28]. In fact, ErbB2 signaling in non-
amplified ErbB2 cells may be abrogated more efficiently
than in tumor cells, given the lower amount of ErbB2
copies. However, pertuzumab does not impede ligand-in-
duced signaling through ErbB4 homodimers or through
ErbB4/ErbB3 heterodimers. It seems plausible that in the
presence of pertuzumab and a reduced availability of
ErbB20s dimerization arms, physiological NRG-1 signaling
shifts towards ErbB2-independent signaling. Pertuzumab
may thus merely modify but not inhibit physiological ErbB
signaling activity. These phenomena may explain why in
clinical trials, pertuzumab has emerged as a safe drug, with
little or no cardiac toxicity.
Lapatinib
The clinical picture
Lapatinib is generally reserved for the late-stage treatment,
and only in combination with capecitabine for ErbB2-
positive breast cancer in women, whose cancer has pro-
gressed following previous chemotherapy with anthracy-
cline, taxanes, and trastuzumab. In combination with
capecitabine, reversible decreases of left ventricular func-
tion occur [5].
Table 4 Action of different ErbB2 antagonist on cancer cells and on ligand (NRG-1)-induced signaling and on cardiac function
Drug Tumor cell Cardiomyocyte
Anticancer mechanism Secondary
Resistance
Effect on NRG-1 signaling Cardiotoxicity
Trastuzumab Inhibition of ErbB2/ErbB3
dimerization by binding
domain IV of the ErbB2
receptor
Yes Inhibits heterotypic ErbB2/




[49, 53] 7 %
Trastuzumab with
anthracyclines: [52] 27 %
Pertuzumab Inhibition of ErBb2/ErbB3
dimerization by binding
domain II of the ErbB2
receptor
No Inhibits heterotypic ErbB2/





Lapatinib Reversible tyrosine kinase
inhibitor of EGFR/ErbB1
and ErbB2
Yes [8] Inhibits heterotypic ErbB2/





Neratinib Irreversible tyrosine kinase
inhibitor of EGFR/ErbB1,
ErbB2 and ErbB4




None reported [4, 48]
Afatinib Irreversible tyrosine kinase
inhibitor of EGFR/ErbB1
and ErbB2
Unknown Inhibits heterotypic ErbB2/
ErbB4 signaling, but not
homotypic ErbB4/ErbB4










Unknown Inhibits heterotypic ErbB2/










Unknown No binding in the heart
given absence of ErbB2/
ErbB3 heterodimers
None
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Lapatinib is a small molecule intracellular and rever-
sible ErbB2- and EGFR/ErbB1 tyrosine kinase inhibitor
(Fig. 6c) [10]. As such, compared with trastuzumab, lap-
atinib has the advantage of inhibiting the phosphorylation
of ErbB3 by ErbB2 in the oncogenic complex, indepen-
dently of whether this complex was formed in a ligand-
dependent or independent way. Hence, single treatment
with lapatinib leaves little room for the development of
drug resistance through ligand-induced ErbB2/ErbB3
oncogenic complexes, thereby mimicking the combination
of trastuzumab plus pertuzumab. Nevertheless, recent
studies indicate that ErbB3 is upregulated in lapatinib-
treated cells and that it may still form ErbB2/ErbB3
complexes with residually active ErbB2 [38].
With regard to its effect on physiological NRG-1/ErbB
signaling, lapatinib clearly abrogates ligand-induced ErbB2
signaling, hence potentially interfering with NRG-1-in-
duced signaling. Similarly, as for pertuzumab, however,
lapatinib should not interfere with ligand-induced ErbB4/
ErbB4 homotypic signaling or through ErbB4/ErbB3 het-
erotypic signaling. This may explain why lapatinib has
emerged as a drug, with little or no cardiac toxicity [50].
Afatinib and neratinib are two second-generation irre-
versible tyrosine kinase inhibitors. Afatinib is highly
selective for EGFR/ErbB1 and ErbB2, whereas neratinib
also inhibits ErbB4, carrying the risk of block both
homotypic and heterotypic signaling (Fig. 6c). No signifi-
cant cardiac dysfunction in phase I and II trials have been
reported for afatinib and neratinib. These early cardiac
safety data are promising [50].
Trastuzumab-emtansine
Trastuzumab-emtansine (also known as T-DM1) is an
antibody conjugate consisting of the monoclonal antibody
trastuzumab linked to cyctotoxic agent emtansine
(Fig. 6d). Trastuzumab targets ErbB2-positive tumors,
whereas emtansine is a highly potent antimicrotubule drug
[29]. This toxic effect is restricted to ErbB2-expressing
cells that result in very little neuropathy and no hair loss
[11]. T-DM1 has a better overall safety profile compared
with trastuzumab. No significant cardiotoxicity was
observed with T-DM1 in patients, previously treated with
trastuzumab and a taxane [24]. Obviously, T-DM1 has
never been tested in treatment schedules that co-adminis-
trated anthracyclins and T-DM1.
MM-111
MM-111 is a new bispecific antibody and polypeptide
fusion protein of two human scFv antibodies linked to
modified human serum albumin (Fig. 6e). The resulting
molecule, MM-111, forms a trimeric complex with ErbB2
and ErbB3, inhibiting ErbB3 signaling and showing anti-
tumor activity in preclinical models that are dependent on
ErbB2 overexpression [38]. By its design, MM-111 blocks
the activity of ligand-dependent and ligand-independent
ErbB2/ErbB3 complexes in tumor cells, hence, recapitu-
lating the effect of combining trastuzumab and pertuzumab
or lapatanib, albeit in a completely different manner. A
recent study demonstrated that MM-111 inhibition of
ligand-activated ErbB3 phosphorylation is superior to
pertuzumab, and that the combination of MM-111 with
trastuzumab more effectively inhibits tumor cell growth
than pertuzumab plus trastuzumab [38]. The underlying
reason is that pertuzumab merely indirectly inhibits ErbB3
activation by precluding ErbB2 dimerization. In tumor
cells with a high number of ErbB2, inhibition of ErbB2 by
pertuzumab may be incomplete. By contrast, MM-111
inactivates ErbB3 in a direct way.
A major advantage of MM-111 is its specific binding to
ErbB2/ErbB3 complexes. Since these complexes are absent
or at least of minor abundance and/or physiological
importance in the heart, it is very unlikely that MM-111
interferes with the physiological function of NRG-1 in the
heart. Accordingly, at least from this perspective, the car-
diotoxic profile of MM-111 should be safe.
Conclusions
The crucial position of ErbB2 at the cross road between
cancer and heart failure has made it an attractive thera-
peutic target in both oncology and cardiology. Growing
knowledge of ErbB2 signaling as well as smart drug design
has gradually led to the development of therapeutics to
target ErbB2 signaling in the right cell type, for safe use in
cancer and heart failure. Molecules, such as bivalent NRG-
1 or MM-111, are exemplary for how a combination of a
detailed understanding of biology and smart drug design
can lead to fascinating progress in a complex medical field.
Further clinical introduction of these drugs is ongoing and
will tell whether these drugs can live up to the
expectations.
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